STEK (Stemtech) Total Liabilities: $11.33 Mil (As of Mar. 2026)


What is Stemtech Total Liabilities?

Stemtech STEK Total Liabilities is $11.33 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Stemtech's Total Liabilities for the quarter that ended in Mar. 2026 was $11.33 Mil.

Stemtech's quarterly Total Liabilities increased from Sep. 2025 ($10.30 Mil) to Dec. 2025 ($10.85 Mil) and increased from Dec. 2025 ($10.85 Mil) to Mar. 2026 ($11.33 Mil).

Stemtech's annual Total Liabilities increased from Dec. 2023 ($6.46 Mil) to Dec. 2024 ($9.01 Mil) and increased from Dec. 2024 ($9.01 Mil) to Dec. 2025 ($10.85 Mil).

Stemtech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Stemtech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stemtech Total Liabilities Chart

Stemtech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 9.73 7.44 6.46 9.01 10.85

Stemtech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.44 10.32 10.30 10.85 11.33

Stemtech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stemtech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.854+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.85

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3.15--7.704
=10.85

Stemtech's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.331+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.33

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=3.253--8.078
=11.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $11.33 Mil mean?
Stemtech (STEK) has a Total Liabilities of $11.33 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Stemtech and its competitors.
Is Stemtech's Total Liabilities too high?
Stemtech's current Total Liabilities is $11.33 Mil.
How does Stemtech's Total Liabilities compare to PTPI and KOAN?
Stemtech's Total Liabilities of $11.33 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Stemtech and its competitors. Stemtech's current Total Liabilities is $11.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stemtech stock overvalued right now?
Based on GuruFocus' analysis, Stemtech (STEK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Total Liabilities is $11.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Stemtech (STEK), the current Total Liabilities is $11.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stemtech Business Description

Address 4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate into tissues, where the stem cells perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from Latin America.